BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36810555)

  • 21. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma.
    Koh YW; Jung SJ; Park CS; Yoon DH; Suh C; Huh J
    Mod Pathol; 2014 Oct; 27(10):1338-44. PubMed ID: 24603587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer.
    Mercier J; Voutsadakis IA
    J Gastrointest Oncol; 2018 Jun; 9(3):478-486. PubMed ID: 29998013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical Characteristics of 219 Patients with Primary Gastrointestinal Non-Hodgkin's Lymphoma].
    Li YY; Hu DZ; Wang YF; Zhao ZG; Cao Z; Zhang YZ; Zhang HL; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):849-854. PubMed ID: 32552946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordant PET Findings and a High Relapse Rate Characterize Hispanics With Hodgkin's Lymphoma Treated With ABVD.
    Gaur S; Philipovskiy A; Onyedika U; Eiring AM; Dwivedi AK; Orazi A
    Cancer Diagn Progn; 2021; 1(3):127-133. PubMed ID: 35399309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of PD-1, FOXP3 and CSF-1R Protein Expression on the Prognosis of Patients with Hodgkin's Lymphoma].
    Li XJ; He L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1372-1377. PubMed ID: 30295253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
    Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
    Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance of ΔSUV
    Yang S; Qiu L; Huang X; Wang Q; Lu J
    Ann Hematol; 2020 Feb; 99(2):293-299. PubMed ID: 31897678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 30. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
    N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
    Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
    [No Abstract]   [Full Text] [Related]  

  • 32. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
    Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
    Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
    Zelenetz AD
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
    Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
    J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin's lymphoma.
    Pinochet P; Texte E; Stamatoullas-Bastard A; Vera P; Mihailescu SD; Becker S
    Sci Rep; 2021 Dec; 11(1):23195. PubMed ID: 34853386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study.
    Lee SF; Luque-Fernandez MA
    BMJ Open; 2017 Nov; 7(11):e017904. PubMed ID: 29101140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
    Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
    Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and severity of neutropenia in diffuse large B-cell non Hodgkin's lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolone.
    Nadeem M; Idrees M; Khattak J; Hussain I; Amin Z; Arif S; Zeeshan M; Hussain M
    J Ayub Med Coll Abbottabad; 2011; 23(1):80-3. PubMed ID: 22830154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.